Table 7.
Scenario 5 (Change in the level of reimbursement rate for all countries to 100%) versus base case–Net pharmaceutical budget impact in 2011 and 2012–2016 for reimbursement rate set at 100% for all countries versus net budget impact 2012–2016 for total pharmaceutical expenditures from healthcare public payer perspective (2011 €, million €)
| Scenario number | Base case | 5 | ||
|---|---|---|---|---|
| Budget impact 2011 | Budget impact 2012–2016 | |||
| Country | France | −5,589 | 11,823 | 3,723 (+9,312 versus base case) |
| Germany | −831 | 4,017 | 3,094 (+3,925 versus base case) | |
| Greece | −808 | 1,010 | 0 (+808 versus base case) | |
| Hungary | −84 | 669 | 544 (+628 versus base case) | |
| Poland | 41 | 1,954 | 2,020 (+1,979 versus base case) | |
| Portugal | −243 | 741 | 443 (+686 versus base case) | |
| United Kingdom | −9,367 | 0 | −9,367 (+0 versus base case) | |